Quarterly report pursuant to Section 13 or 15(d)

NOTE 9 - STOCKHOLDERS' DEFICIT

v3.21.1
NOTE 9 - STOCKHOLDERS' DEFICIT
3 Months Ended
Mar. 31, 2021
Notes  
NOTE 9 - STOCKHOLDERS' DEFICIT

NOTE 9 - STOCKHOLDERS’ DEFICIT

 

Reverse Stock Split

 

On November 11, 2020, ZIVO’s stockholders approved a reverse stock split of its common stock within the range of 1-for-25 to 1-for-120 of our authorized, issued, and outstanding shares of common stock. The Board, in its discretion, will determine the final ratio, effective date, and date of filing of the certificate of amendment to our articles of incorporation, as amended, in connection with the reverse stock split. The Board has not yet finalized the stock-split, therefore all option, share and per share information in this Quarterly Report on Form 10Q does not give effect to any proposed reverse stock split.

 

Stock Issuances

 

During the three months ended March 31, 2021, the Company issued 7,726,264 shares at an average price of $0.135 for proceeds of $1,040,000, to private investors. In addition, during this same period, a related party purchased 357,142 shares of the Company’s common stock at $0.14 per share for proceeds of $50,000.

 

During the three months ended March 31, 2020, the Company issued 156,252 shares at $0.16 per share for proceeds of $25,000, to private investors.

 

Stock Warrants Exercised

 

During the quarter ended March 31, 2021, warrants to purchase 50,000 shares of the Company’s common stock were exercised on a “cashless” basis resulting in the issuance of 22,973 shares of common stock.

 

During the three months ended March 31, 2020, HEP Investments, a principal shareholder and related party, assigned warrants to purchase 3,750,000 shares of the Company’s common stock to third party investors. These warrants were exercised at $0.10 per share resulting in proceeds of $375,000. Due to the nature of this transaction, the Company considered the warrants to be contributed capital from a majority shareholder and recorded equity related finance charges. The warrants were valued at $453,441 using the Black Scholes pricing model relying on the following assumptions: volatilities ranging from 128.20% to 142.46%; annual rate of dividends 0%; discount rates ranging from 0.66% to 1.65%.

 

In addition, the Company issued 10,000 shares of the Company’s common stock at $0.10 per share for proceeds of $1,000 from the exercise of warrants.

 

Sale of Common Stock Warrants

 

In connection with the License Co-Development Participation Agreements (“Participation Agreements”) (see Note 8), the Company sold warrants to purchase 315,000 shares of common stock for $40,799. The warrants were valued based on the Black Scholes pricing model relying on the following assumptions: volatility 139.55% to 149.20%; annual rate of dividends 0%; discount rate 0.41% to 0.45%.

 

2019 Omnibus Long-Term Incentive Plan

 

On November 29, 2019, after approval from the Board, the Company entered into and adopted the 2019 Omnibus Long-Term Incentive Plan (the “2019 Incentive Plan”) for the purpose of enhancing the Registrant’s ability to attract and retain highly qualified directors, officers, key employees and other persons and to motivate such persons to improve the business results and earnings of the Company by providing an opportunity to acquire or increase a direct proprietary interest in the operations and future success of the Company. The 2019 Incentive Plan will be administered by the compensation committee of the Board who will, amongst other duties, have full power and authority to take all actions and to make all determinations required or provided for under the 2019 Incentive Plan. Pursuant to the 2019 Incentive Plan, the Company may grant options, share appreciation rights, restricted shares, restricted share units, unrestricted shares and dividend equivalent rights. The Plan has a duration of 10 years.

 

Subject to adjustment as described in the 2019 Incentive Plan, the aggregate number of common shares (“Shares”) available for issuance under the 2019 Incentive Plan is One Hundred Two Million (102,000,000) Shares. The exercise price of each Share subject to an Option (as defined in the 2019 Incentive Plan) shall be at least the Fair Market Value (as defined in the 2019 Incentive Plan) (except in the case of an incentive stock option granted to more than 10% shareholder of the Company, in which case the price should not be less than 110% of the Fair Market Value) on the date of the grant of a Share and shall have a term of no more than ten years. As of March 31, 2021, 62,500,000 Options have been issued with terms between 5 years and 10 years. Based on certain performance milestones, the grant agreements also provide for the issuance of an additional 12,000,000 options of the Company’s common stock at an exercise price of at least the Fair Market Value (as defined in the 2019 Omnibus Long-term Incentive Plan) on the date of the grant of a Share and with a term of no more than ten years.

 

Common Stock Options

 

A summary of the status of the Company’s Options related to the 2019 Incentive Plan is presented below:

 

 

 

March 31, 2021

 

December 31, 2020

 

 

Number of

Options

 

Weighted

Average

Exercise

Price

 

Number of

Options

 

Weighted

Average

Exercise

Price

Outstanding, beginning of year

 

48,500,000

$

0.12

 

-

$

-

Issued

 

14,000,000

 

0.14

 

48,500,000

 

0.12

Outstanding, end of period

 

62,500,000

$

0.13

 

48,500,000

$

0.12

 

Options outstanding and exercisable by price range as of March 31, 2021 were as follows:

 

 

Outstanding Options

 

Exercisable Options

 

Range of

Exercise

Price

 

Number

 

Average

Weighted

Remaining

Contractual

Life in Years

 

Range of

Exercise

Price

 

Number

 

Weighted

Average

Exercise Price

$

0.10-0.109

 

28,000,000

 

8.63

$

0.10-0.109

 

28,000,000

$

0.10

 

0.11-0.119

 

2,000,000

 

4.48

 

0.11-0.119

 

625,000

 

0.11

 

0.12-0.129

 

2,000,000

 

4.38

 

0.12-0.129

 

1,000,000

 

0.12

 

0.14-0.149

 

15,000,000

 

9.69

 

0.14-0.149

 

5,000,000

 

0.14

 

0.15-0.159

 

2,000,000

 

8.93

 

0.15-0.159

 

2,000,000

 

0.15

 

0.16-0.169

 

13,500,000

 

3.89

 

0.16-0.169

 

10,000,000

 

0.16

 

 

 

62,500,000

 

7.60

$

 

 

46,625,000

$

0.12

 

Common Stock Warrants

 

A summary of the status of the Company’s warrants is presented below:

 

 

March 31, 2021

 

December 31, 2020

 

Number of

Warrants

 

Weighted

Average

Exercise

Price

 

Number of

Warrants

 

Weighted

Average

Exercise

Price

Outstanding, beginning of year

200,177,006

$

0.09

 

194,204,339

$

0.09

Issued

315,000

 

0.14

 

23,005,000

 

0.12

Exercised

(50,000)

 

0.08

 

(14,365,000)

 

0.10

Cancelled

-

 

-

 

-

 

-

Expired

(125,000)

 

0.09

 

(2,667,333)

 

0.08

Outstanding, end of period

200,317,006

$

0.09

 

200,177,006

$

0.09

 

Warrants outstanding and exercisable by price range as of March 31, 2021 were as follows:

 

 

Outstanding Warrants

 

Exercisable Warrants

 

Exercise

Price

 

Number

 

Average

Weighted

Remaining

Contractual Life

in Years

 

Exercise

Price

 

Number

 

Weighted

Average

Exercise Price

 

$

0.05

 

1,000,000

 

0.45

$

0.05

 

1,000,000

$

0.05

 

0.06

 

16,050,000

 

1.34

 

0.06

 

16,050,000

 

0.06

 

0.07

 

2,500,000

 

1.45

 

0.07

 

2,500,000

 

0.07

 

0.08

 

30,368,477

 

2.15

 

0.08

 

30,368,477

 

0.08

 

0.09

 

100,000

 

1.33

 

0.09

 

100,000

 

0.09

 

0.10

 

124,773,734

 

2.12

 

0.10

 

124,773,734

 

0.10

 

0.11

 

3,704,795

 

2.98

 

0.11

 

3,704,795

 

0.11

 

0.12

 

18,555,000

 

4.45

 

0.12

 

18,555,000

 

0.12

 

0.14

 

2,865,000

 

2.75

 

0.14

 

2,865,000

 

0.14

 

0.18

 

400,000

 

3.75

 

0.18

 

400,000

 

0.18

 

 

 

200,317,006

 

2.29

 

 

 

200,317,006

$

0.10